Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC2A1 | P11166 | 3/20 | 0.39 |
| ▸ | ADRB3 | P13945 | 9/20 | 0.39 |
| ▸ | ADRB1 | P08588 | 4/20 | 0.39 |
| ▸ | ADRB2 | P07550 | 2/20 | 0.39 |
| ▸ | HAT1 | O14929 | 3/20 | 0.38 |
| ▸ | EP300 | Q09472 | 3/20 | 0.38 |
| ▸ | FAAH | O00519 | 1/20 | 0.37 |
| ▸ | SFRP1 | Q8N474 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6679483 | 1.00 | SLC2A1 (0.39) | SLC2A1ADRB3ADRB1ADRB2HAT1 | |
| SCHEMBL6676613 | 0.95 | SIGMAR1 (0.39) | SLC2A1ADRB3ADRB1ADRB2FAAH | |
| SCHEMBL6678770 | 0.88 | ADRB3 (0.43) | ADRB3ADRB1HAT1EP300 | |
| SCHEMBL6679660 | 0.85 | CTSD (0.40) | SLC2A1ADRB3ADRB1ADRB2HAT1 | |
| SCHEMBL6681905 | 0.85 | TUBB (0.41) | SLC2A1ADRB3ADRB1ADRB2HAT1 | |
| SCHEMBL6676287 | 0.84 | ADRB3 (0.55) | ADRB3ADRB1 | |
| SCHEMBL6272839 | 0.84 | KMT2A (0.42) | SLC2A1ADRB3ADRB1 | |
| SCHEMBL6677803 | 0.83 | ADRB3 (0.54) | ADRB3ADRB1 | |
| SCHEMBL6272911 | 0.83 | KMT2A (0.42) | SLC2A1ADRB3HAT1EP300 | |
| SCHEMBL6679246 | 0.83 | ADORA1 (0.40) | SLC2A1ADRB3ADRB1ADRB2HAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2004045610-A1 | AMINOALCOHOL DERIVATIVES AND THEIR USE AS BETA-3 ADRENERGIC RECEPTOR AGONISTS | FUJISAWA PHARMACEUTICAL CO., LTD (JP) | 2004-06-03 | — | — | WO | disclosed |